IL-12-TM

IL-12-TM is a tumor-targeted, membrane-anchored form of interleukin-12 (IL-12) designed to enhance antitumor immune responses while minimizing systemic toxicity. Interleukin-12 is a heterodimeric cytokine composed of p35 and p40 subunits, known for its ability to drive T helper 1 (Th1) immune responses and activate both innate and adaptive immunity. By anchoring IL-12 to the cell membrane or targeting it specifically to tumors, IL-12-TM aims to localize cytokine activity within the tumor microenvironment, thereby expanding local immune responses, reducing systemic side effects such as cytokine release syndrome, and overcoming immunosuppressive mechanisms in tumors. This approach leverages the potent immunostimulatory properties of IL-12—such as activation of T cells and natural killer (NK) cells—to induce interferon-gamma production and promote antitumor activity[2][3][5]. Preclinical studies have shown that tumor-targeted forms like IL-12TM-D can enhance anti-tumor efficacy in various models[3]. Clinical development is ongoing.